Treatment with brentuximab vedotin plus bendamustine in unselected patients with CD30‐positive aggressive lymphomas

OBJECTIVES: A treatment regimen consisting of bendamustine and brentuximab vedotin (BV) has been described as a highly potent salvage therapy and as an effective induction therapy leading to high response rates before autologous stem cell transplantation (ASCT) in patients with classical Hodgkin lym...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Eur J Haematol
Main Authors: Wagner, Sandro M., Melchardt, Thomas, Egle, Alexander, Magnes, Teresa, Skrabs, Cathrin, Staber, Philipp, Simonitsch‐Klupp, Ingrid, Panny, Michael, Lehner, Barbara, Greil, Richard, Keil, Felix, Jäger, Ulrich, Sillaber, Christian
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2020
Teme:
Original Articles
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7065019/
https://ncbi.nlm.nih.gov/pubmed/31838747
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ejh.13368
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki